Table 1 Baseline demographics and patient characteristics
Characteristic | Number of patients (N = 41) |
|---|---|
Age, years | |
Median (range) | 54 (30–73) |
Sex | |
Male | 1 (2.4%) |
Female | 40 (97.6%) |
Race | |
White | 33 (80.5%) |
Black or African American | 5 (12.2%) |
Unknown | 3 (7.3%) |
Ethnicity | |
Hispanic or Latino | 6 (14.6%) |
Not Hispanic or Latino | 30 (73.2%) |
Unknown | 5 (12.2%) |
ECOG Performance Status | |
0 | 19 (46.3%) |
1 | 22 (53.7%) |
Prior lines of systemic therapy | |
(locally advanced unresectable or metastatic disease) Mean | 1.7 |
1 | 21 (51.2%) |
2 | 10 (24.4%) |
3 | 10 (24.4%) |
Prior neoadjuvant or adjuvant chemotherapy | |
Yes | 33 (80.5%) |
No | 8 (19.5%) |
Prior targeted systemic anticancer therapy | |
Yes | 20 (48.8%) |
No | 21 (51.2%) |
Prior radiation therapy | |
Yes | 35 (85.4%) |
No | 6 (14.6%) |
BRCA1/2 germline deleterious mutation status | |
Mutated | 4 (9.8%) |
Wildtype | 19 (46.3%) |
Unknown | 18 (43.9%) |
Number of metastatic sites | |
1 | 16 (39.0%) |
2 | 14 (34.1%) |
≥ 3 | 11 (26.8%) |
Sites of metastasis | |
Lung | 15 (24.4%) |
Lymph nodes | 20 (48.8%) |
Liver | 15 (24.4%) |
Bone | 16 (39.0%) |
Chest wall | 8 (19.5%) |
Other | 6 (14.6%) |